Amylin Said to Seek Buyers After Rejecting Bristol-Myers

Amylin Pharmaceuticals Inc., the maker of the diabetes drugs Bydureon and Byetta, is seeking a buyer after rejecting an unsolicited bid from Bristol-Myers Squibb Co., two people with knowledge of the matter said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.